Collegium Pharmaceutical, Inc. Lands $20,000,000 Series D Funding Round

  • Feed Type
  • Date
  • Company Name
    Collegium Pharmaceutical, Inc.
  • Mailing Address
    400 Highland Corporate Drive Cumberland, RI 02864
  • Company Description
    Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs. We apply customized pharmaceutical formulations and intellectual property (IP) strategies to drugs that are safe and effective, creating a portfolio of improved pharmaceutical products with a shorter time to market.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    The proceeds from this financing will be used primarily to support the continued development of the Company’s lead DETERx™ product candidate, COL-003, a tamper resistant, abuse-deterrent, sustained release oxycodone formulation.
  • M&A Terms
  • Venture Investor
    Frazier Healthcare Ventures
  • Venture Investor
    Boston Millennia Partners

Trending on Xconomy